Publications by authors named "Pierre E Signore"

Claim this Profile
H
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy.
Zhen Guo, Anahita Ataran, Pan Ma, Wenjing Yu, Hamidreza Hajirezaei, Pierre E Signore

Circulation· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell Mobilization.
Min Wu, Dennis C Koester, Gail Walkinshaw, Danny Ng, Xiaoti Zhou, Pierre E Signore

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Pierre E Signore, Guangjie Guo, Zhihua Wei, Weihua Zhang, Al Lin

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Ughetta Del Balzo, Pierre E Signore, Gail Walkinshaw, Todd W Seeley, Mitchell C Brenner

J Pharmacol Exp Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.
Mitchell C Brenner, Wojciech Krzyzanski, James Z Chou, Pierre E Signore, Cyra K Fung

Pharm Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis